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Abstract 
We present the case of a 19-year-old female with a history of Down syndrome (DS) who was 
referred to our neuro-ophthalmology clinic for evaluation of Leber’s hereditary optic 
neuropathy (LHON). The patient’s family history was significant for a known G11778A 
mutation in a maternal relative, consistent with LHON. The patient was also positive for the 
G11778A mutation; however, the genotype demonstrated low penetrance in the pedigree, 
with only 1 out of 10 adult male offspring showing signs or symptoms of the disease. 
Mitochondrial mutations implicated in LHON have been shown to impair complex I of the 
electron transport chain and thereby reducing the effective generation of adenosine 
triphosphate and increasing the production of toxic reactive oxygen species. Although the 
partial or complete triplicate of chromosome 21 constitutes the etiology of DS, some of the 
pleiotropic phenotypes of the syndrome have been attributed to oxidative stress and 
mitochondrial dysfunction. Given the low penetrance of the mutation and the patient’s sex, 
this case illustrates the possibility that the mitochondrial mutation demonstrated increased 
penetrance due to pre-existing mitochondrial dysfunction related to DS. © 2014 S. Karger AG, Basel 
Introduction 
Leber’s hereditary optic neuropathy (LHON) is a debilitating, blinding mitochondrial 
disease with subacute onset and rapid progression at a young age. The 3 most common 
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mutations of LHON, including those at mtDNA positions 11778, 3460 and 14484, account for 
approximately 95% of cases worldwide, and affect different subunits of complex I, the first 
complex of the electron transport chain [1]. The most common locus is 11778/ND4. 
Dysfunction of the complex I molecule may inhibit specific cellular mechanisms, including 
the generation of adenosine triphosphate via oxidative phosphorylation, the biosynthesis of 
amino acids and the reduction of cytotoxic reactive oxygen species [2]. These deficits appear 
to preferentially reduce the viability of retinal ganglion cells, thereby leading to the clinical 
findings of retinal nerve fiber layer thinning, although the precise mechanism of this 
phenomenon remains an area of contention. Carriers of a known mtDNA mutation may 
never express symptoms of the disease, as factors affecting penetrance include hetero-
plasmy, environmental influences, the mitochondrial background as well as nuclear 
modifying genes [3]. In the pathogenesis of Down syndrome (DS), Valenti et al.  [4] described 
mitochondrial dysfunction as a result of a defect in the oxidative phosphorylation machinery, 
specifically related to a defect in the complex I molecule. Indeed, recent investigations have 
demonstrated that reduced visual acuity and retinopathy are frequent in DS [5]. In this case, 
a patient with concomitant DS expressed a low-penetrance familial mutation, the 
11778/ND4 genotype, raising the possibility that underlying mitochondrial dysfunction in 
DS lowers the threshold for expression of the LHON phenotype. 
Case Presentation 
Prior to visiting our clinic, a 19-year-old female with a history of DS presented to an 
outside ophthalmology clinic for the evaluation of reduced visual acuity. Based on the 
observations by her family members, the patient had a 1-year history of a marked decrease 
in ‘visual activities’. The patient’s past medical history was significant for DS and sensorineu-
ral hearing loss. It was also notable for duodenal atresia repair 10 years prior to presenta-
tion. Her family history was significant for only 1 male cousin with LHON. One unaffected 
member of the extended family had previously undergone documented genetic testing for 
the LHON mutation, which revealed that a sister of the patient’s grandmother was a carrier 
of the 11778 mutation. Additionally, several maternal relatives of the patient reported 
positivity for the mutation, although evidence from previous genetic analysis could not be 
found. Given that all maternal offspring would be expected to be carriers of the disease, 
there were 25 unaffected carriers of the mutation, of which 9 were male heirs (fig. 1) [6]. 
The patient was referred to our clinic approximately 1 year after her diagnosis. On 
examination, visual acuity was 20/200 bilaterally. There was no relative afferent pupillary 
defect, though Amsler grid testing revealed bilateral central scotomata. Color plate testing 
revealed 5/6 color plates bilaterally. The patient had 10 diopters of esotropia on straight 
gaze with full ductions, and the intraocular pressures were 17 and 19 mm/Hg, respectively. 
An examination of the anterior segment, her lens and the vitreous were unremarkable. 
Dilated fundus examination demonstrated pale optic nerves and bilateral cup-to-disc ratios 
of 0.8 (fig. 2). The retina was otherwise unremarkable. A generalized neurological examina-
tion demonstrated a mild cognitive impairment. 
Six months prior to her visit, the patient had undergone an MRI of the head and orbits 
for evaluation of compressive, ischemic or demyelinating disease. MRI had revealed an 
increased T2 signal within the optic chiasm and the optic nerves bilaterally, suggestive of a 
metabolic or mitochondrial disorder. Subsequent mitochondrial genetic testing was 
performed via pyrosequencing, and the LHON G11778A mutation was confirmed. In our 
clinic, the patient was unable to complete a Humphrey visual field examination or tangent 
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field testing; therefore, a Goldmann visual field was administered in order to confirm the 
presence of central field defects (fig. 3). Though the patient had poor fixation, bilateral 
central scotomata were present. Subsequent optical coherence tomography of the optic 
nerve head demonstrated a mild thinning of the retinal nerve fiber layer, with an average 
retinal nerve fiber layer thickness measuring 81 μm OD and 77 μm OS. The average cup-to-
disc ratio was noted to be 0.81 OD and 0.75 OS. 
Treatment 
Prior to her visit at our clinic, the patient had been started on idebenone 150 mg t.i.d. 
Idebenone is a short-chain benzoquinone that acts on the mitochondrial electron transport 
chain to improve cellular respiration. It has been proposed that idebenone allows electrons 
to bypass complex I, effectively maintaining the production of ATP despite an alteration of 
complex I [6]. Recent studies have demonstrated the therapeutic efficacy of idebenone in 
treating LHON; therefore, treatment with this agent was continued [7]. Results of a recent 
trial of idebenone 900 mg/day in patients with LHON demonstrated safety and tolerability at 
this dose, and the dose for the patient was increased from 150 mg t.i.d. to 150 mg q.i.d. to 
account for her recent increase in body mass index [8]. She was asked to return to the clinic 
every 4 months for ongoing neuro-ophthalmology assessment. 
Discussion 
LHON is a disease of the mitochondria in which a mutation in mtDNA leads to a pheno-
type of optic nerve atrophy secondary to the attrition of the retinal ganglion cell layer of the 
retina. LHON presents as subacute painless vision loss, usually in young men, and has a 
reported prevalence of 3.2 in 100,000, though there appears to be variability between 
populations [9]. Though the disease is acquired via maternal inheritance, women who 
harbor one of the primary mutations have an approximately 10% risk of developing optic 
nerve atrophy, while men have a risk as high as 50% [10]. This sex bias suggests that 
environmental and gender-specific genetic factors are superimposed on the penetrance of 
the mutation [11]. In the above case, the patient’s family history was notable for having a 
single male relative who was affected by an LHON 11778 mutation. There were 26 family 
members who were unaffected carriers of the mutation and who did not express the disease 
phenotype, indicative of a low-penetrance mutation. Acquired causes of mitochondrial 
dysfunction have been shown to trigger the development of LHON, including pharmacologic 
agents such as chloramphenicol [12] and ethambutol [13]. Similarly, it is a reasonable 
hypothesis that the patient’s co-expression of the DS phenotype, with superimposed 
dysfunction of the oxidative phosphorylation pathway, led to the predisposition for 
developing signs and symptoms of LHON. 
The chief clinical features of DS (or Trisomy 21) are neurological and cognitive deficien-
cies, but there is also a predisposition for neoplastic disease and sequelae of accelerated 
aging, such as dementia and osteoporosis [14]. Although the partial or complete triplicate of 
chromosome 21 constitutes the etiology of DS, some of the pleiotropic phenotypes of the 
syndrome have been attributed to oxidative stress and mitochondrial dysfunction. In 1998, 
mitochondrial structural abnormalities in a mouse model of DS were found to include 
abnormally shaped mitochondria, abnormal filaments and microtubule deficiency [15]. 
Deficiencies of mitochondrial enzymes involved in oxidative phosphorylation, including 
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monoamine oxidase, cytochrome oxidase and isocitrate dehydrogenase, were found in 
platelets of patients with DS, suggesting that mitochondria in DS were susceptible to 
oxidative damage [16]. Druzhyna et al. [17] showed that mitochondria in DS are indeed more 
vulnerable to oxidative damage as a result of the aberrant expression of CuZn superoxide 
dismutase, perhaps leading to the accelerated development of phenotypes associated with 
aging. In a mouse model of DS, superoxide formation was increased by more than 50% when 
compared to controls, indicating an increased mitochondrial oxidative burden in DS [18]. It 
is therefore possible that otherwise low-penetrance mutations of LHON may be more easily 
expressed when coupled with an underlying progeroid syndrome, such as DS, and concomi-
tant mitochondrial dysfunction. 
It is possible that heteroplasmy, or the unequal distribution of mutated mitochondrial 
DNA amongst cells, played a role in the penetrance of the mutation. However, the patient’s 
family reported that 3 maternal relatives had undergone genetic testing, revealing positivity 
for the mitochondrial mutation. These individuals did not demonstrate signs or symptoms of 
conversion. Although the status of these individuals as carriers could not be confirmed, it is 
likely that they were indeed positive for the 11778 mutation. Furthermore, the 11778 
mutation tends to progress toward homoplasmy in successive generations; yet, the 
aforementioned pedigree did not reflect an increased incidence of conversion [19]. 
This case demonstrates the possibility of a ‘two-hit’ hypothesis in the expression of a 
low-penetrance LHON mutation when coupled with a pre-existing mitochondrial dysfunc-
tion. In considering the differential diagnosis of subacute vision loss in patients with DS and 
other genetic diseases with mitochondrial dysfunction, a high clinical suspicion for LHON 
should be raised, and molecular characterization by DNA blood testing should be performed. 
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Fig. 1. Family pedigree. Note that only 1 maternal family member, with the exception of the proband, had 
documented genetic testing. 
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Fig. 2. Goldmann perimetry was used to evaluate the peripheral visual fields. a OS and b OD. Note the 
centrocecal scotomas OU. 
 
 
 
Fig. 3. Fundus photos. a OD and b OS. 
 
